---
title: "Sensei Biotherapeutics (now Faeth Therapeutics) regains Nasdaq bid price"
url: "https://aibio.space/news/sensei-biotherapeutics-now-faeth-therapeutics-regains-nasdaq-bid-price/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-07-09"
section: "Listings"
tickers: "NASDAQ:FTH"
source: "https://www.sec.gov/Archives/edgar/data/1829802/000119312525157113/d64284d8k.htm"
summary: "Nasdaq staff found the stock closed at $1.00 or more for 10 consecutive business days, from June 17, 2025 to July 1, 2025."
---

By the aibio.space news desk.

Sources

- [Faeth Therapeutics, Inc. 8-K (2025-07-09)](https://www.sec.gov/Archives/edgar/data/1829802/000119312525157113/d64284d8k.htm)

[FTH](https://aibio.space/companies/faeth-therapeutics/)

2025-07-09

# Sensei Biotherapeutics (now Faeth Therapeutics) regains Nasdaq bid price compliance

Tickers [FTH](https://aibio.space/companies/faeth-therapeutics/)

Nasdaq staff found the stock closed at $1.00 or more for 10 consecutive business days, from June 17, 2025 to July 1, 2025.

## Key facts

- **Company**: Faeth Therapeutics, Inc. (NASDAQ: FTH)

- **News type**: Listings

- **Primary source**: [Faeth Therapeutics, Inc. 8-K (2025-07-09)](https://www.sec.gov/Archives/edgar/data/1829802/000119312525157113/d64284d8k.htm)

*The White House and its lawn. CC0, via rawpixel. The picture shows the field, not the companies named.*

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), now Faeth Therapeutics, Inc., said it has regained compliance with Nasdaq's minimum bid price rule.

In an [8-K filed July 9, 2025](https://www.sec.gov/Archives/edgar/data/1829802/000119312525157113/d64284d8k.htm), the Rockville, Maryland company said it received a letter on July 2, 2025 from the Listing Qualifications Staff of The Nasdaq Stock Market LLC. The staff determined that for 10 consecutive business days, from June 17, 2025 to July 1, 2025, the closing bid price of the company's common stock was at $1.00 per share or greater.

As a result, the staff found the company had regained compliance with Nasdaq Listing Rule 5550(a)(2). That rule requires listed companies to keep a minimum bid price of $1.00 per share. A company whose stock closes below that level for too long receives a deficiency notice and must lift its price within a set period or face delisting.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

FTH

Faeth Therapeutics, Inc.

NASDAQ · United States

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/sensei-biotherapeutics-now-faeth-therapeutics-regains-nasdaq-bid-price/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Sensei Biotherapeutics (now Faeth Therapeutics) regains Nasdaq bid price", 2025-07-09, https://aibio.space/news/sensei-biotherapeutics-now-faeth-therapeutics-regains-nasdaq-bid-price/